The management of Lupin is confident of scaling back $ 200 million quarterly revenue run rate for US market by Q3, but at the same time, alluded to overall EBITDA margin guidance of 16-17 per cent in FY22
Lupin
PRO Only Highlights
– Quarterly performance largely backed by improved realisations
– Medium-term triggers China plus and protectionist measures for tyre industry
– Valuations not inexpensive; but improved medium-term outlook
Lupin’s (CMP: Rs 976; Market Cap: Rs 44,328 crore) quarterly result was weaker on account of elevated competitive pressures in the US market, which is now reflected in lower sales run rate and margin guidance downgrade. Though the company has a strong pipeline for inhalation and injectables, monetisation of the same will catch up from next fiscal. Hence, in the absence of a near-term catalyst, Lupin warrants caution as the twin risk of pricing erosion and regulatory risk have come…
